Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?

HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.

NVO : 136.79 (+3.36%)
HCA : 258.08 (+0.03%)
AVEO : 15.00 (unch)
LIVN : 58.14 (+0.16%)
GSK Signs Deal to Develop Antibodies for Treating Cancer

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

GSK : 34.83 (-0.85%)
AVEO : 15.00 (unch)
AMRN : 1.8900 (-3.08%)
ALLO : 7.78 (-5.24%)
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

MRK : 102.94 (-0.50%)
MRNA : 173.25 (-1.76%)
AVEO : 15.00 (unch)
ALLO : 7.78 (-5.24%)
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA

The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.

BMRN : 112.20 (-0.57%)
AVEO : 15.00 (unch)
AMRN : 1.8900 (-3.08%)
ALLO : 7.78 (-5.24%)
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

AVEO : 15.00 (unch)
WVE : 5.15 (-0.96%)
VRNA : 21.19 (+3.37%)
CABA : 12.31 (+0.98%)
4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

AVEO : 15.00 (unch)
WVE : 5.15 (-0.96%)
VRNA : 21.19 (+3.37%)
CABA : 12.31 (+0.98%)
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

AVEO : 15.00 (unch)
MMSI : 73.33 (-0.12%)
Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?

Here is how Basilea Pharmaceutica AG (BPMUF) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

BPMUF : 52.0000 (+13.04%)
AVEO : 15.00 (unch)
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

AVEO : 15.00 (unch)
QURE : 22.52 (+0.67%)
ETON : 3.49 (+0.58%)
IMCR : 64.29 (+1.21%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 15.00 (unch)
ETON : 3.49 (+0.58%)
IMCR : 64.29 (+1.21%)
PALI : 2.73 (-0.73%)

Barchart Exclusives

Friday's Last Call: Crude Oil's Hard Fall
The WTI crude oil market fell hard Friday, but there was much more to the selloff than just January's nonfarm payrolls number. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar